Measles outbreaks in the US are the result of choice. To get vaccinated or not. But there’s another vaccine-preventable disease that’s making a global comeback—whooping cough or pertussis.

Since 2011, whooping cough has become the most common cause of hospitalisation and death in infants in the UK. Australia, too, saw a particularly severe epidemic between 2008-10. In 2010-11, California experienced its largest whooping cough outbreak in 50 years. Similarly, the incidence of whooping cough has increased in both Norway and Canada as well.

Explore more infographics like this in The Ken -
Visual Stories

All from a disease that is potentially preventable through a routine vaccination.

The signs of resurgence are fast becoming evident in India, too. Although there is no officially reported nationwide data on incidence of pertussis till date, Indian doctors have begun to raise red flags. Like Arjun Padmanabhan, a specialist in respiratory diseases at the Kerala Institute of Medical Sciences in Thiruvananthapuram, Kerala. Every now and again, one of Padmanabhan’s patients let out a worrying noise while coughing—the ‘whoop’ sound associated with pertussis.

“Over the last few years, I have started diagnosing cases of whooping cough once or twice a year,” he says. And each time, he wonders why an ‘ancient disease,’ preventable with a vaccine used in the government-funded universal immunisation programme (UIP) since the seventies, is still showing up. After all, India’s UIP has been largely successful in controlling most vaccine-preventable diseases, such as polio, due to its reach in the public health system.

What is whooping cough?

Whooping cough or pertussis is a bacterial infection leading to a nasty cough. It can last for up to three months in adults. In children, it spreads very easily and can even be deadly. While government programmes using effective and long-lasting vaccines also offer herd immunity to the entire population, less effective, short-lived vaccines can compromise this.

When he looked deeper, he found that this resurgence, too, is born of choice. Not about whether to vaccinate, but rather what vaccine to use. The older, more painful vaccine used in the UIP or the newer, second generation vaccine sold by pharma majors GlaxoSmithKline (GSK) and Sanofi Pasteur. Almost counter-intuitively, it is the latter, introduced in developed countries in the 1990s and later in private markets of developing countries, that is being linked with the global resurgence of pertussis.

In developed countries, this makes sense. Governments in these countries have overwhelmingly favoured the second generation vaccine.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.